CJC-1295 / Ipamorelin

What it is

This is the GH stack — the single most popular growth-hormone-secretagogue combination in the wellness and biohacking world, and for a coherent reason. It pairs the two peptides that drive your GH pulses from two different directions: CJC-1295 (no-DAC), the GHRH analog that raises your GH baseline, and Ipamorelin, the selective ghrelin-receptor agonist that fires a clean GH pulse. Two receptors, one stack, a bigger pulse than either delivers alone.

The framing that matters: this blend doesn’t inject growth hormone into you. It signals your own pituitary to release more of the GH you already make, in your natural pulsatile rhythm, with your body’s somatostatin brake intact. That’s the physiologic-restoration approach one practitioner contrasts against exogenous HGH — and it’s the whole logic of running these two together. As he puts it, married together they “rewire your entire human operating system” — restoring declining endogenous GH signaling rather than replacing it.

How it works

Your GH pulses are driven by two upstream signals: GHRH and ghrelin. They run through separate receptors. CJC-1295 binds the GHRH receptor (more signal, raised baseline GH). Ipamorelin binds the ghrelin receptor, GHS-R1a, firing a clean pulse without the cortisol/prolactin splash of older secretagogues. Your pituitary cells express both receptors — so stimulating both at once means more receptor occupancy, convergent calcium/cAMP signaling, and an amplified GH pulse.

The cleanest lay-translation of this synergy comes from Dr. Ashley Froese: think of your pituitary as the DJ at a party. GHRH peptides like CJC-1295 walk into the DJ booth and say “play that song”: they wake up the natural pulse pattern. Ipamorelin is the hype man: “It runs to the DJ and says, ‘Turn it up, man.’ And so the DJ will drop a more potent, more bumping song.” CJC-1295 increases the frequency of GH pulses; Ipamorelin increases the amplitude of each pulse. Plus Ipamorelin quiets somatostatin — the hormone that normally tells the pituitary to shut up: which reduces the background noise and makes the signal cleaner. Increased frequency + increased amplitude + cleaner signal = the synergy that makes the dual stack outperform either peptide alone. (A parallel practitioner-friendly framing from Dr. Jones DC: CJC-1295 is the gas pedal — it pushes the pituitary to release more GH. Ipamorelin releases the brake — it turns down the body’s built-in shutoff signal. One pushes; one stops-blocking; the pulse that comes out is bigger than either could produce alone.) Ipamorelin’s unique clean-amplifier advantage — no cortisol / prolactin / hunger bumps that GHRP-2, GHRP-6, and Hexarelin produce — is why it’s the preferred GHRP partner in this stack. And the larger reframe worth carrying: peptides do not replace growth hormone. They wake the natural pulse pattern back up — the pituitary you already have, doing the job it already did at 25, just with the DJ booth back online. That’s the physiologic-restoration story that differentiates GHRH+GHRP secretagogue stacks from exogenous GH replacement.

This is real, class-level human pharmacology, not just theory. One practitioner cites a “2018 European Journal of Endocrinology” study for combined GHRH + ghrelin-agonist administration exceeding the sum of each alone — that specific cite doesn’t resolve, but the underlying phenomenon is verified in humans: Hataya et al. 2001 (JCEM) showed a low dose of ghrelin stimulates GH release synergistically with GHRH in humans. Supra-additive GH release from a GHRH analog plus a GH-releasing peptide is well-established in the endocrine literature (the Veldhuis/Bowers line of work). One practitioner’s “~40% greater GH elevation” and the “slows tachyphylaxis” claims are his own framing, not numbers from that literature.

So the mechanism here is strong and well-grounded: dual-pathway pulse amplification, supported by Hataya 2001’s human GHRH+ghrelin synergy data and the established pharmacology of each component. Here is the honest signal, stated plainly and confidently: there is no human RCT on the CJC-1295 + Ipamorelin combination itself. The blend rests entirely on each component’s separately-trialed mechanism plus the human GHRH+ghrelin synergy in Hataya 2001 [PMID 11549707]. That is exactly how a well-reasoned research-grade stack is built — from validated parts — and it doesn’t undercut the mechanism; it just means the combination’s effect size in humans hasn’t been measured head-to-head.

What the research shows

The full picture, every tier labeled, honestly mapped.

Dual-receptor synergy. The strongest evidence is the established human pharmacology of giving a GHRH stimulus and a ghrelin/GH-releasing peptide together: the GH response is supra-additive — bigger than either alone. Hataya 2001 is the clean human demonstration of GHRH + ghrelin synergy, reinforced by the broader Veldhuis/Bowers GHRH+GHRP literature. This is the scientific spine of the blend — and it’s a component-pathway result, not a trial of the blend itself.

The components, individually:

• CJC-1295 (with-DAC) has a human RCT (Teichman 2005) proving sustained GH/IGF-1 elevation and good short-term tolerability. It preserves pulsatility and works in animal proof-of-concept.
• Ipamorelin has proven clean selectivity (GH up, cortisol/prolactin untouched), confirmed human PK [PMID 26811125, 10496658], and a human ileus RCT in which it was well tolerated.
• Foundational GH-axis evidence the benefit logic rests on: Rudman 1990 NEJM (GH replacement improves lean mass / reduces fat in older men) and Brioche 2014 (GH prevents sarcopenia + mitochondrial biogenesis in rats).

Combination-specific data. A 2026 peptide-therapy review that names the pair points to a mouse model of improved tetanic muscle tension under steroid-induced atrophy, and notes the combination’s clinical specifics are still being characterized [REVIEW citing ANIMAL, PMID 41476424]. Several other 2026 reviews catalog the pair as a widely-used GH-secretagogue combination [REVIEW, PMIDs 41490200, 42021992, 42160466, 41880199].

The body-composition story — lean mass, fat loss, recovery, sleep — is built on GH/IGF-1 physiology plus the substantial real-world use base, not yet on a controlled human trial of the blend itself. The real anchor under it is GH-replacement evidence: Rudman 1990 NEJM (lean mass up, fat down in older men, PMID 2355952) and Brioche 2014 (GH prevents sarcopenia + mitochondrial biogenesis, PMID 24300031). One practitioner maps the downstream chain — restored GH → IGF-1 → muscle protein synthesis (mTOR/AKT), satellite-cell activation, reduced myostatin, mitochondrial biogenesis (PGC-1α), fat mobilization — which is coherent physiology. His specific marquee-journal claims with precise percentages (“BDNF +45%,” “muscle ATP +35%,” “GH ↑ telomerase,” “hippocampal neurogenesis,” “+25% coronary flow,” “−40% HOMA-IR,” “lean mass +6–8 lb/month”) did not survive PubMed verification — the journal/number attributions aren’t in the literature, so they’re dropped here in favor of the qualitative GH-axis benefits tied to the real sources above. That’s the honest, complete map — exactly where a bleeding-edge GH stack sits, and not a reason it doesn’t deliver.

Real-world protocol

The doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.

This is the protocol the community and practitioners use, from a commonly used practitioner protocol.

Standard blend protocol:

• Dose: 250 mcg CJC-1295 + 250 mcg ipamorelin per dose, AM and PM
• Schedule: 5 days on / 2 off
• Cycle: 8 weeks on, then off
• Reconstitution: 5 mg / 5 mg vial + 2 ml bacteriostatic water = 2,500 mcg/ml of each peptide. A 250 mcg dose = 0.10 ml = 10 units on a U-100 insulin syringe (delivers 250 mcg of each, since they’re co-dosed in the same vial).

Timing: Commonly run at night and/or fasted, to ride the natural overnight GH pulse. Food near the dose (especially carbs/fat) blunts the GH response — fasted dosing is why most people inject before bed and/or first thing. The specific mechanism, worth being blunt about [ESTABLISHED endocrinology]: eating — especially anything insulinogenic — spikes your insulin, and that insulin response acutely suppresses the pituitary’s GH release. So you inject, the signal-to-release goes out, then the snack you had an hour ago shuts the pulse down before it goes anywhere. Dr. Jones DC’s operational framing for this (paraphrased): you paid for the gas pedal and then hit the brake — the money went into triggering the pulse, and the food an hour before shut the pulse back down. The rule that follows: inject at least a couple hours after your last meal, and don’t eat into the fasted window right after the shot. Pre-bed injection is where this rule lands most cleanly for most people because it aligns with the body’s own overnight pulse.

⚠️ If you’re stacking with a GLP-1 receptor agonist (Retatrutide, Semaglutide, Tirzepatide), the standard “2 hours after eating” rule isn’t long enough. GLP-1 activity slows gastric emptying — food sits in the stomach for ~3 hours rather than 2, with measurably more retained at the 2-hour mark and the gap widening at 3 hours. The “dinner at 7, pin at 9” convention fails on a GLP-1 because insulin from the partially-absorbed meal suppresses the GH pulse at the pituitary. Move CJC/Ipa to first thing in the morning when on a GLP-1, and eat 30-60 min after injection (gives the pulse time to fire + anchors the post-meal insulin to the IGF-1 conversion in the liver). Full rule + sources in Retatrutide § Stacking.

Where experts differ: surface this: The blend convention above uses CJC-1295 no-DAC daily. One practitioner’s preferred approach pairs ipamorelin with CJC-1295 with-DAC dosed roughly once weekly, arguing it gives more consistent IGF-1 and slower tachyphylaxis. He also flags an apparent tension: in another talk he argues against constant single-vial mega-dosing — yet CJC+ipamorelin is sold pre-blended industry-wide. The reconciliation is that his caution is about constant, unpulsed exposure desensitizing receptors, not about co-formulation per se; the blend is still run in pulses on a cycle. Both the no-DAC daily blend (what Alyve stocks, what most people start with) and the with-DAC weekly approach are legitimate.

Cycling: 8-week blocks with breaks is the community default; one practitioner’s general rule is to cycle GH-axis peptides rather than run them continuously, to keep receptors responsive. Do not load all your doses into a single shot — spaced, pulsatile dosing is the point. A slightly different macro-cycle from Dr. Jones DC: run 5-days-on / 2-off weekly for the weekly micro-break that keeps receptors responsive, then take about a month off every 4–6 months as the bigger reset — so the GH axis doesn’t get tired of hearing the signal. Jones is honest about the limits of the evidence here: the exact reset cadence is not proven to precise science; it’s the cautious way to run it. Both the 8-week-block convention and the 4-6-month macro-cycle land in the same range and encode the same principle — cycle it, do not run it continuously.

Advanced stacking: one practitioner layers the blend with MOTS-C (mitochondrial signal), BPC-157 (which he says raises GH-receptor expression and IGF-1 tissue uptake), and retatrutide (metabolic partitioning) for what he calls a “metabolic thermonuclear reactor” — each maps to an Alyve SKU. These are his clinical-opinion stacks, run as separate compounds, and the specific synergy figures carry.

If your run seems to be doing nothing: the four things to check

This is the honest version of a pattern that shows up over and over in the peptide community: someone runs CJC-1295 + Ipamorelin for a couple months, sees nothing in the mirror, decides the whole thing was a scam. Sometimes it was — supply-chain quality is real (see below). But most of the time the compound isn’t the problem; the execution is. The four checks below, from Dr. Jones DC’s diagnostic framing, cover the failure modes that account for almost every “it did nothing for me” story.

1. What you ate before the shot. This is the big one. Insulin acutely suppresses the GH pulse, so injecting an hour after a carb-heavy meal is the single most reliable way to waste the dose — the pulse fires and then gets shut down before it goes anywhere. Fix: inject at least a couple hours after your last meal, and protect the fasted window right after. Pre-bed is where this lands cleanly for most people. (Full mechanism in the timing paragraph above.)

2. The version and the route you’re using. These peptides are fragile. Transdermal creams and nasal sprays are marketed as convenient, but they don’t reliably deliver enough of the dose into circulation to matter. Subcutaneous injection is the route that actually works. If someone sold you a cream or a spray as “just as good as injecting,” it isn’t. And on the version question specifically — CJC-1295 exists in a no-DAC form (short half-life, sharp pulse; what Alyve stocks; what the blend convention uses) and a with-DAC form (long half-life, days-long GH elevation). The blend here uses no-DAC. If the vial you have is with-DAC, the daily-blend protocol above doesn’t apply — that’s a different regimen entirely (once-weekly, closer to one practitioner’s approach), and you should not run it on this schedule.

3. You quit too early. This is a hormone-level tool, not a steroid. Recovery gains, sleep quality, and body-composition shifts build over months — not the four-week window most people are actually running. Compare to the Holyfield timeline in the KB: sleep improves in weeks 1–2, recovery in weeks 2–4, fat loss beginning at 8–12 weeks, collagen and joint effects at months 3–6. Someone who bails at week 4 is bailing before the results were ever supposed to show. Run it long enough to actually let it compound.

4. You never cycled it, and the receptors quit responding. The flip side of quitting too early. Running Ipamorelin continuously with no breaks and the GH axis stops responding to the signal — the system gets tired of hearing it. The convention above (5-on / 2-off weekly + roughly a month off every 4–6 months) exists to keep the axis responsive so each run hits like the first one. Skip cycling and you get the pattern where “it stopped working” — and it did, but because the protocol was off, not because the peptide failed.

The underneath-all-this fifth thing: you might not actually know what’s in the vial. The gray-market peptide space is genuinely rough — independent lab testing on gray-market vendors consistently finds underdosed and mislabeled product (see the 25%-fake analysis in ). You can run the perfect protocol on a fake product and get zero. The honest fix is not more careful protocol — it’s a verified vendor with a real third-party COA. That’s what Alyve and BioLongevity actually solve (see the Alyve product section below for the COA specifics).

Notice what’s not on any of these lists — the molecule itself. The compound is almost never the problem. The four things above (plus supply-chain quality) account for nearly every “it did nothing for me” report. That’s the honest read: fixable execution, not a compound that failed.

Who this stack is — and isn't — for

A clean decision-tree framing from Dr. Kristi Sawicki (PhD molecular oncology) that captures the OHM foundation-first thesis exactly. “Growth hormone peptides are not working in a vacuum. You can’t just inject a peptide, ghost it on your couch, and expect to be beefed up.”. The stack amplifies adaptation — it does not create it. For the stack to translate into real outcomes, three things have to be in place:

1. Mechanical stimulus from resistance training — the muscle-tear / adaptation signal that GH and IGF-1 then operate on. Without it, there is no substrate for the signal to act on.
2. Adequate protein + calories — for the downstream signal to actually be executable. Without it, the building blocks for repair aren’t available.
3. Sufficient recovery — for the tissue to rebuild. Continuously breaking down without rebuilding doesn’t move the dial.

“You can think of growth hormone peptides as sort of turning up the repair crew. But if no construction work is happening, then there’s nothing to repair.”.

Three case-study illustrations for whether the stack fits a given reader profile:

Reader profile	GH-axis fit?
47yo male on TRT, low IGF-1, poor sleep, visceral fat, low energy, already strength-training	Yes — TRT doesn’t fix the GH-axis decline; the secretagogue stack addresses sleep, visceral fat, recovery, and body composition simultaneously.
50yo female, lean, hormonally optimized, training 3×/week but plateaued on muscle gain	Yes — adds the permissive recovery signal that the training is asking for; test IGF-1 first to confirm she’s not already at the top of the U-curve; cycle.
40s female, moderate-to-high IGF-1, sleep issues, insulin resistance, NOT resistance training	No: fix the foundation first. The issue is metabolic and lifestyle. GH peptides on this baseline won’t move any levers and are not worth the cost. Resistance training + metabolic-health work + sleep first; reassess after.

The third case is the OHM-editorial credibility move: the most informed answer to “should I run GH peptides?” is sometimes “not yet: fix the foundation first.” That’s not gatekeeping; it’s the pharmacology being honest about the input-output relationship. And it pairs naturally with the IGF-1 Goldilocks U-curve framing in IGF-1 LR3 and MGF — the IGF-1 axis muscle cluster — running secretagogues into already-high IGF-1 pushes you to the wrong side of the curve.

Side effects & management

No combination-specific safety trial exists, so the safety picture is inferred from the components — both of which were well tolerated in their human trials. Component RCTs: ipamorelin had adverse events below placebo in the ileus trial; CJC-1295 showed no serious AEs short-term.

What users report:

• A brief hunger spike after dosing (the ipamorelin/ghrelin effect) — usually mild, fades within the hour.
• Flushing and warmth shortly after injection.
• Mild water retention if GH signaling is pushed too hard — one practitioner’s fix is to dial the dose back until it disappears. One practitioner and Bakri both note this is the main “too much” signal and it’s easily managed.
• Injection-site reactions, occasional headache or lightheadedness, sometimes transient joint discomfort.

The longer-term considerations, stated plainly: Keep IGF-1 in your age-adjusted physiologic range and check it periodically on longer runs. One practitioner’s framing — physiologic restoration (~2–3× normal GH/IGF-1) rather than the supraphysiologic flood of exogenous HGH — is the sensible target, and he argues secretagogues are safer than HGH precisely because they preserve pulsatility and your somatostatin brake. On cancer, he rebuts the blanket fear. His own “2004 JCEM ~6,200-patient” cite doesn’t resolve, but the real evidence supports him: a 2016 meta-analysis (9 studies, 11,191 participants) found GH-replacement therapy in GH-deficient adults was associated with reduced cancer risk (RR 0.69), and the large SAGhE European cohort found no clear excess cancer risk in patients without other major disease. Conservative defaults: avoid with active cancer, uncontrolled diabetes, or significant cardiovascular disease; long-term human safety data for the blend specifically doesn’t yet exist.

The real variable is sourcing, not the molecules. Both Bakri and one practitioner converge here: the dominant safety issue with peptides is supply-chain quality — purity, identity, contamination — not the compounds themselves. The gray market is batch-to-batch unknown. That’s exactly why a third-party COA (below) is the thing to verify before you buy.

🚨 Histamine / mast-cell activation: under-discussed but real (added 2026-06-16). A subset of users — particularly those with pre-existing histamine intolerance, autoimmune conditions, or mast-cell-activation syndrome (MCAS) — can develop a histamine-driven reaction to the GH-axis peptides. Sermorelin and CJC-1295 are the most common triggers, but Tesamorelin can also activate the response. The diagnostic tell: injection sites become itchy and red, and the irritation does NOT resolve within ~an hour (normal injection-site irritation resolves quickly; histamine-driven irritation persists). If ignored, it can escalate to full-body itching, flushing, and in some cases uterine cramping…

In midlife women specifically: estrogen fluctuations during perimenopause can sensitize mast cells and increase histamine reactivity — meaning a user who had been tolerating the peptide fine can develop a new histamine reaction as estrogen patterns shift. Worth knowing for the symptomatic-reader audience this is specifically relevant to.

Management options:

1. Pause or lower the dose if the histamine reaction starts.
2. Switch from subcutaneous to intramuscular (IM) injection. Sawicki’s most-reliable practical fix: “Because we don’t have the immune cells in the muscle, it doesn’t seem to trigger that response.”. The mechanism is plausible — the dermal mast-cell layer that gets sensitized on subcutaneous injection is largely absent in intramuscular tissue.
3. Stop the peptide entirely if the reaction does not resolve with the above adjustments.

Implication for the symptomatic-reader audience: if you have a known history of histamine intolerance, MCAS, autoimmune flares, or perimenopausal mast-cell-sensitivity symptoms, expect this risk to be higher than the standard side-effect framing suggests and start at the low end of the dose range with extra-cautious site rotation.

Regulatory status

Not FDA-approved. Both components were placed on the FDA’s 503A Category 2 bulk-substances list in October 2023, restricting compounding for human use. WADA prohibits both in sport (Section S2). Everything sold is research-use-only.

The Alyve product

This is the buyable, verified one. Alyve’s CJC-1295 + Ipamorelin Blend (5 mg / 5 mg, CJC-1295 in the no-DAC form) is IN STOCK at $68.00 (on sale from $78.00), with a Certificate of Analysis at 99.90% purity — tested by Freedom Diagnostics Testing, an independent third party, using HPLC-UV for purity and LC-MS for identity confirmation (lot CJI583, samples received 05/27/2026). Net content came in at 5.36 mg ipamorelin — over label.

That’s the conversion angle in one line: in a market where essentially all raw peptide material flows through a stringency-graded supply chain and the gray-market tier is batch-to-batch unknown for both purity and identity, a third-party COA at 99.90% with mass-spec-confirmed identity is the verified-clean tier. Alyve’s own copy also stays in the research-use lane and doesn’t make the inflated “1000% GH” claims that float around clinic pages — to its credit.

Offer: Use coupon OHM-15 for 15% off (brings the blend to ~$57.80) — Alyve’s pricing is very competitive, and buying 3 vials of any given peptide in one purchase gets you over 30% off retail. (Full disclosure: OHM-15 also attributes the sale to me — I’d rather say it plainly than tuck it in fine print.)

Sources

1. Teichman SL, et al. CJC-1295 (with DAC) GH/IGF-1 RCT (component). J Clin Endocrinol Metab. 2005. : 16352683
2. Beck DE, et al. Ipamorelin Phase 2 RCT (component) — well tolerated. Int J Colorectal Dis. 2014. : 25331030
3. Raun K, et al. Ipamorelin selectivity (component). Eur J Endocrinol. 1998. : 9849822
4. Ionescu M, Frohman LA. Pulsatile GH persists during CJC-1295 (component). J Clin Endocrinol Metab. 2006. : 17018654 4a. Hataya Y, et al. Ghrelin + GHRH synergistic GH release in humans (the synergy spine). J Clin Endocrinol Metab. 2001. : 11549707 4b. Rudman D, et al. GH in men over 60 (foundational GH body-comp RCT). N Engl J Med. 1990. : 2355952 4c. Brioche T, et al. GH prevents sarcopenia + mitochondrial biogenesis (rat). J Gerontol A Biol Sci Med Sci. 2014. : 24300031
5. Mayfield CK, et al. Injectable peptide therapy primer (names the pair; animal model). Am J Sports Med. 2026. : 41476424
6. Mavrych V, et al. Therapeutic peptides in gerontology — review. Front Aging. 2026. : 42021992
7. Villegas Meza AD, et al. Injectable peptides in sports medicine — review. JBJS Rev. 2026. : 42160466
8. Rahman OF, et al. Therapeutic peptides in orthopaedics — review. JAAOS Glob Res Rev. 2026. : 41490200
9. Coutinho LFD, et al. Peptide/peptide-analog drugs in sport — review. J Sports Med Phys Fitness. 2026. : 41880199 9a. Gobburu JV, et al. Ipamorelin PK/PD modeling in human volunteers (terminal t½ 2 h). Pharm Res. 1999. : 10496658 9b. Li Z, et al. GH replacement reduces cancer risk in GH-deficient adults — meta-analysis (RR 0.69). Oncotarget. 2016. : 27835910 9c. Swerdlow AJ, et al. Cancer risks after childhood GH treatment (SAGhE European cohort). J Clin Endocrinol Metab. 2017. : 28184422
10. Video digest — one practitioner CJC-1295/Ipamorelin Masterclass (40% synergy, 2018 Eur J Endocrinol, anti-HGH thesis). 10a. Video digest — Holyfield CJC-1295/Ipamorelin mechanism + timeline (DAC vs no-DAC, benefit timeline, 200-300 mcg dosing). 10b. Video digest — Dr. Jones DC CJC-1295 + Ipamorelin execution mistakes (gas-pedal/brake-release metaphor, insulin timing rule, Four Execution Mistakes framework, 4-6 month macro-cycle).
11. Dosing/reconstitution cheat sheet (one practitioner).
12. Alyve COA summary (blend 99.90%, lot CJI583).
13. Alyve Peptides — CJC-1295 + Ipamorelin Blend. / https://alyvepeptides.com/product/cjc-1295-ipamorelin-blend/

See also: CJC-1295, Ipamorelin, Sermorelin, Tesamorelin.